China National Biotec Group
http://www.cnbg.com.cn
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From China National Biotec Group
Boosters Miss Growth Expectations Despite China COVID Surge
While two Chinese companies gained domestic approvals for their recombinant protein and adenovirus-based COVID-19 shots as heterologous boosters in February, these currently only account for roughly 21% of all booster shots, showing the continued predominance of inactivated virus-based technology in the country.
China OKs Heterologous Booster Shots Amid Heated COVID Vaccine Race
CanSino and Zhifei have received the regulatory green light for their respective COVID-19 booster shots in China and an estimated $1.3bn vaccine market is now up for grabs. Domestic contenders are set to elbow each other in the sector with a range of viral vector, recombinant protein and mRNA-based jabs.
Pfizer, CStone Score China's Seventh Immuno-Oncology Approval
Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.
With No mRNA Vaccines In Sight, Frustration Grows In China
A top virologist and prominent Chinese researcher sounds alarm over reluctance to clear mRNA vaccines amid regional outbreaks and the government rollout of inactivated virus-based booster shots without real-word evidence.